There is no system of banning drugs globally by any organization or regulation. The safety and efficacy of a drug is ascertained as per Schedule Y of Drugs and Cosmetics Rules before market approval in the country. Even after market approval is given for any drug, the safety and efficacy is continuously examined on the basis of information received through Pharmoco-vigilance, Post-Marketing Surveillance and information reported from other countries.
In order to examine such information, the Drug Technical Advisory Board under Drugs & Cosmetics Act has constituted a Sub-committee, consisting of experts on the subject who examine the information received from the sources mentioned above and take a final view as to whether the prohibit the manufacture, sale and distribution of drugs or restrict its use for specific population and accordingly recommend to the Government to make suitable amendment in the market authorization or prohibit manufacture, sale and distribution and drugs under Section 26A of the Drugs & Cosmetics Act which empowers the Central Government to prohibit the manufacture, sale or distribution of such drug or cosmetics.
No information has been received in the Directorate General of Health Services (DGHS) regarding availability in the market of drugs banned in the country under Section 26A of the Drugs & Cosmetics Act.